MA38801A1 - Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant - Google Patents

Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant

Info

Publication number
MA38801A1
MA38801A1 MA38801A MA38801A MA38801A1 MA 38801 A1 MA38801 A1 MA 38801A1 MA 38801 A MA38801 A MA 38801A MA 38801 A MA38801 A MA 38801A MA 38801 A1 MA38801 A1 MA 38801A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinoline compounds
novel isoindoline
Prior art date
Application number
MA38801A
Other languages
English (en)
Other versions
MA38801B1 (fr
Inventor
Diguarher Thierry Le
Jérôme-Benoît Starck
Jean-Michel Henlin
I-Jen Chen
Olivier Geneste
Tiran Arnaud Le
Miklos Nyerges
Nanteuil Guillaume De
James Davidson
James Murray
Claire Walmsley
Mark Dodsworth
Johannes Meissner
Paul Brough
Imre Fejes
Janos Tatai
Andras Kotschy
Zoltan Szlavik
Anne-Françoise Guillouzic
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA38801A1 publication Critical patent/MA38801A1/fr
Publication of MA38801B1 publication Critical patent/MA38801B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de formule (i) : (i) dans laquelle het, r3, r4, r5, r7, r8, r9, t, p, p', q, et q' sont tels que définis dans la description, des agents pro-apoptotiques utiles dans le traitement de cancers et de maladies auto-immunes et des maladies du système immunitaire.
MA38801A 2013-07-23 2014-07-22 Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant MA38801B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (fr) 2013-07-23 2014-07-22 Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
MA38801A1 true MA38801A1 (fr) 2018-05-31
MA38801B1 MA38801B1 (fr) 2019-03-29

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38801A MA38801B1 (fr) 2013-07-23 2014-07-22 Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant

Country Status (49)

Country Link
US (3) US9809574B2 (fr)
EP (1) EP3024826B1 (fr)
JP (1) JP6395829B2 (fr)
KR (1) KR102008431B1 (fr)
CN (2) CN109456324B (fr)
AP (1) AP2016008989A0 (fr)
AR (1) AR097009A1 (fr)
AU (1) AU2014295101B2 (fr)
BR (1) BR112016001080B1 (fr)
CA (1) CA2919572C (fr)
CL (1) CL2016000148A1 (fr)
CR (1) CR20160030A (fr)
CU (1) CU24352B1 (fr)
CY (1) CY1121247T1 (fr)
DK (1) DK3024826T3 (fr)
DO (1) DOP2016000009A (fr)
EA (1) EA032301B1 (fr)
ES (1) ES2711371T3 (fr)
FR (1) FR3008977A1 (fr)
GE (2) GEP20207070B (fr)
HK (1) HK1218754A1 (fr)
HR (1) HRP20190277T1 (fr)
HU (1) HUE041443T2 (fr)
IL (1) IL243449A0 (fr)
JO (1) JO3457B1 (fr)
LT (1) LT3024826T (fr)
MA (1) MA38801B1 (fr)
MD (1) MD4793C1 (fr)
ME (1) ME03346B (fr)
MX (1) MX365373B (fr)
MY (1) MY193619A (fr)
NI (1) NI201600016A (fr)
NZ (1) NZ716155A (fr)
PE (1) PE20160241A1 (fr)
PH (1) PH12016500034A1 (fr)
PL (1) PL3024826T3 (fr)
PT (1) PT3024826T (fr)
RS (1) RS58344B1 (fr)
RU (1) RU2689305C2 (fr)
SA (1) SA516370439B1 (fr)
SG (1) SG11201600205XA (fr)
SI (1) SI3024826T1 (fr)
TN (1) TN2016000003A1 (fr)
TR (1) TR201819155T4 (fr)
TW (1) TWI560184B (fr)
UA (1) UA117490C2 (fr)
UY (1) UY35664A (fr)
WO (1) WO2015011164A1 (fr)
ZA (1) ZA201600198B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3445762B1 (fr) 2016-04-20 2023-09-13 Bristol-Myers Squibb Company Composes heterocycliques bicyliques substitues
WO2020006296A1 (fr) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
KR20230160303A (ko) * 2021-03-24 2023-11-23 르 라보레또레 쎄르비에르 ５－｛５－클로로－２－[(3s)－３－[(모르폴린－４－일)메틸]－３,４－디하이드로이소퀴놀린－２(１ｈ)－카르보닐]페닐｝－１,２－디메틸－１ｈ－피롤－３－카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도
AR128587A1 (es) 2022-02-24 2024-05-22 Servier Lab Derivados de 5-[7-(3,4-dihidro-1h-isoquinolina-2-carbonil)-1,2,3,4-tetrahidroisoquinolin-6-il]-1h-pirrol-3-carboxamida, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
US20260098022A1 (en) * 2023-03-31 2026-04-09 Mitsui Chemicals, Inc. Carbamate compound
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (fr) * 2003-05-01 2004-11-11 Glaxo Group Limited Derives d'acyle isoindoline et d'acyle isoquinoline utilises comme agents antiviraux
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
BRPI0514504A (pt) * 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用
US20080227792A1 (en) * 2005-02-15 2008-09-18 Novo Nordisk A/S 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
WO2009102463A2 (fr) 2008-02-14 2009-08-20 Connor Reynolds Système et appareil à vide pour déjections d'animaux de compagnie, revêtements internes jetables pour ceux-ci, et procédé de collecte de déjections d'animaux de compagnie les utilisant
CN103732589B (zh) * 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
AU2012355623A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2798432A4 (fr) 2011-12-27 2015-07-22 Intel Corp Procédés et systèmes de commande de réseaux d'alimentation électrique pendant un état actif d'un domaine à déclenchement périodique en fonction de conditions de charge du domaine à déclenchement périodique
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MX2016000904A (es) 2016-04-25
HK1222856A1 (en) 2017-07-14
US9809574B2 (en) 2017-11-07
CN105431422B (zh) 2019-08-30
GEAP201914063A (en) 2019-10-25
US20200262816A1 (en) 2020-08-20
MX365373B (es) 2019-05-31
PT3024826T (pt) 2019-01-28
GEP20207070B (en) 2020-02-25
AU2014295101A1 (en) 2016-02-04
AR097009A1 (es) 2016-02-10
ES2711371T3 (es) 2019-05-03
SA516370439B1 (ar) 2019-06-27
EP3024826A1 (fr) 2016-06-01
JP2016525529A (ja) 2016-08-25
PL3024826T3 (pl) 2019-05-31
PH12016500034B1 (en) 2016-03-28
EP3024826B1 (fr) 2018-11-14
TW201504228A (zh) 2015-02-01
RU2689305C2 (ru) 2019-05-27
UY35664A (es) 2015-01-30
CU20160010A7 (es) 2016-06-29
NZ716155A (en) 2019-05-31
IL243449A0 (en) 2016-02-29
US20160194304A1 (en) 2016-07-07
JP6395829B2 (ja) 2018-09-26
HUE041443T2 (hu) 2019-05-28
JO3457B1 (ar) 2020-07-05
LT3024826T (lt) 2019-02-25
MY193619A (en) 2022-10-20
ZA201600198B (en) 2019-07-31
CU24352B1 (es) 2018-07-05
WO2015011164A1 (fr) 2015-01-29
MA38801B1 (fr) 2019-03-29
BR112016001080A2 (fr) 2017-07-25
MD20160018A2 (ro) 2016-07-31
CA2919572A1 (fr) 2015-01-29
DOP2016000009A (es) 2016-03-15
TWI560184B (en) 2016-12-01
EA201600122A1 (ru) 2016-07-29
NI201600016A (es) 2016-02-11
PH12016500034A1 (en) 2016-03-28
EA032301B1 (ru) 2019-05-31
FR3008977A1 (fr) 2015-01-30
BR112016001080B1 (pt) 2022-04-05
SI3024826T1 (sl) 2019-03-29
CN109456324A (zh) 2019-03-12
CR20160030A (es) 2016-03-09
CY1121247T1 (el) 2020-05-29
US11028070B2 (en) 2021-06-08
KR102008431B1 (ko) 2019-08-07
HRP20190277T1 (hr) 2019-04-05
CL2016000148A1 (es) 2016-08-12
CN105431422A (zh) 2016-03-23
RS58344B1 (sr) 2019-03-29
CA2919572C (fr) 2017-06-20
RU2016106003A (ru) 2017-08-28
SG11201600205XA (en) 2016-02-26
CN109456324B (zh) 2022-04-22
PE20160241A1 (es) 2016-04-30
MD4793B1 (ro) 2022-02-28
HK1218754A1 (zh) 2017-03-10
AU2014295101B2 (en) 2018-05-31
MD4793C1 (ro) 2022-09-30
US20180002313A1 (en) 2018-01-04
TR201819155T4 (tr) 2019-01-21
KR20160033224A (ko) 2016-03-25
TN2016000003A1 (en) 2017-07-05
DK3024826T3 (en) 2019-03-04
US10689364B2 (en) 2020-06-23
UA117490C2 (uk) 2018-08-10
ME03346B (fr) 2019-10-20
AP2016008989A0 (en) 2016-01-31

Similar Documents

Publication Publication Date Title
MA38801B1 (fr) Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MD4516C1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA38483A1 (fr) Inhibiteurs de l'ido
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA43160B1 (fr) Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA35895B1 (fr) Inhibiteurs d'iap
MA44948A1 (fr) Inhibiteurs de bace 1
MA38190A2 (fr) Inhibiteurs d'autotaxine
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT